Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,959,545
  • Shares Outstanding, K 44,912
  • Annual Sales, $ 2,877 M
  • Annual Income, $ 1,195 M
  • EBIT $ 1,377 M
  • EBITDA $ 1,450 M
  • 60-Month Beta 0.64
  • Price/Sales 4.94
  • Price/Cash Flow 11.15
  • Price/Book 2.19

Options Overview Details

View History
  • Implied Volatility 33.29% ( +0.10%)
  • Historical Volatility 43.98%
  • IV Percentile 73%
  • IV Rank 65.23%
  • IV High 39.93% on 08/05/24
  • IV Low 20.82% on 05/09/24
  • Put/Call Vol Ratio 57.75
  • Today's Volume 235
  • Volume Avg (30-Day) 473
  • Put/Call OI Ratio 1.11
  • Today's Open Interest 3,578
  • Open Int (30-Day) 4,308

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 6.29
  • Number of Estimates 7
  • High Estimate 7.07
  • Low Estimate 5.76
  • Prior Year 6.17
  • Growth Rate Est. (year over year) +1.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
299.47 +2.86%
on 03/13/25
324.57 -5.10%
on 03/18/25
-15.60 (-4.82%)
since 02/27/25
3-Month
299.47 +2.86%
on 03/13/25
383.51 -19.68%
on 02/19/25
-51.94 (-14.43%)
since 12/27/24
52-Week
221.53 +39.04%
on 04/01/24
417.82 -26.28%
on 11/08/24
+64.75 (+26.62%)
since 03/27/24

Most Recent Stories

More News
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

BMRN : 72.83 (+1.89%)
VRTX : 502.55 (+0.45%)
MRNA : 32.12 (+2.03%)
UTHR : 308.02 (-0.90%)
BIIB : 140.33 (-1.47%)
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off

CHE : 612.36 (+0.52%)
HIMS : 31.92 (-4.32%)
UTHR : 308.02 (-0.90%)
2 Value Stocks on Our Watchlist and 1 to Ignore

2 Value Stocks on Our Watchlist and 1 to Ignore

DHI : 130.08 (+0.54%)
UTHR : 308.02 (-0.90%)
PRKS : 47.43 (-1.04%)
Why United Therapeutics (UTHR) Stock Is Down Today

Why United Therapeutics (UTHR) Stock Is Down Today

UTHR : 308.02 (-0.90%)
United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations

United Therapeutics (NASDAQ:UTHR) Reports Q4 In Line With Expectations

UTHR : 308.02 (-0.90%)
United Therapeutics: Q4 Earnings Snapshot

United Therapeutics: Q4 Earnings Snapshot

UTHR : 308.02 (-0.90%)
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

MYGN : 9.22 (+0.11%)
BMRN : 72.83 (+1.89%)
UTHR : 308.02 (-0.90%)
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?

United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?

UTHR : 308.02 (-0.90%)
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the disease.This...

JNJ : 163.13 (+0.87%)
MRK : 87.60 (-0.58%)
UTHR : 308.02 (-0.90%)
1 AI Stock Cathie Wood Is Buying Instead of Tesla

Cathie Wood is shifting away from Tesla, zeroing in on an AI-driven healthcare firm that is revolutionizing precision medicine and advanced diagnostics.

TSLA : 273.13 (+0.39%)
ARKG : 22.24 (-1.11%)
TEM : 51.97 (-2.40%)
UTHR : 308.02 (-0.90%)
ARKK : 50.78 (-1.70%)
BNTX : 95.40 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by...

See More

Key Turning Points

3rd Resistance Point 325.92
2nd Resistance Point 322.16
1st Resistance Point 315.09
Last Price 308.02
1st Support Level 304.26
2nd Support Level 300.50
3rd Support Level 293.43

See More

52-Week High 417.82
Fibonacci 61.8% 342.83
Fibonacci 50% 319.67
Last Price 308.02
Fibonacci 38.2% 296.51
52-Week Low 221.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar